Suppr超能文献

血清人附睾分泌蛋白4(HE4)是非小细胞肺癌潜在的预后生物标志物。

Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.

作者信息

Mo Dongping, He Fang

出版信息

Clin Lab. 2018 Sep 1;64(9):1421-1428. doi: 10.7754/Clin.Lab.2018.180222.

Abstract

BACKGROUND

Human epididymis secretory protein 4 (HE4) is a secreted glycosylated protein belonging to the WFDC family, which is an ideal biomarker in ovarian cancer. However, the role of HE4 in lung cancer is still unclear. The study aimed to evaluate serum levels of HE4 as a prognostic biomarker in patients with non-small cell lung cancer (NSCLC).

METHODS

The subjects consisted of 217 NSCLC patients, which were compared to a control group of 80 patients with benign lung disease and 110 healthy controls. Serum levels of HE4 were measured with electrochemiluminescence assays in a Roche E601 Immunoassay Analyzer.

RESULTS

Serum levels of HE4 in NSCLC patients were significantly higher than in benign lung disease and healthy controls (p < 0.001). Using the cutoff value of 78.84 pmol/L, HE4 levels differentiated NSCLC from healthy controls with a sensitivity of 84.2% and a specificity of 78.3%. In the NSCLC subgroups, HE4 was a better discriminator of lung adenocarcinoma (cutoff value, 72.70 pmol/L, area under curve, 0.909; 95% confidence interval, 0.871 - 0.947). Higher serum HE4 levels were significantly correlated with histological type, high TNM stage, and positive lymph node metastasis (p = 0.019, 0.018, 0.002, respectively). Kaplan-Meier analysis demonstrated that high HE4 levels predicted poor survival (log-rank test: p = 0.007), especially in the adenocarcinoma group (logrank test: p = 0.001). In the Cox model, serum HE4 level was an independent prognostic factor for NSCLC.

CONCLUSIONS

Higher serum levels of HE4 predict poor prognosis in NSCLC patients, especially in patients with adenocarcinoma.

摘要

背景

人附睾分泌蛋白4(HE4)是一种属于WFDC家族的分泌型糖蛋白,是卵巢癌的理想生物标志物。然而,HE4在肺癌中的作用仍不清楚。本研究旨在评估血清HE4水平作为非小细胞肺癌(NSCLC)患者预后生物标志物的价值。

方法

研究对象包括217例NSCLC患者,并与80例良性肺病患者和110例健康对照组成的对照组进行比较。采用罗氏E601免疫分析分析仪通过电化学发光法检测血清HE4水平。

结果

NSCLC患者血清HE4水平显著高于良性肺病患者和健康对照组(p < 0.001)。以78.84 pmol/L为临界值,HE4水平区分NSCLC与健康对照的灵敏度为84.2%,特异性为78.3%。在NSCLC亚组中,HE4对肺腺癌的鉴别能力更强(临界值为72.70 pmol/L,曲线下面积为0.909;95%置信区间为0.871 - 0.947)。血清HE4水平升高与组织学类型、高TNM分期及阳性淋巴结转移显著相关(分别为p = 0.019、0.018、0.002)。Kaplan-Meier分析表明,高HE4水平预示生存不良(对数秩检验:p = 0.007),尤其是在腺癌组(对数秩检验:p = 0.001)。在Cox模型中,血清HE4水平是NSCLC的独立预后因素。

结论

血清HE4水平升高预示NSCLC患者预后不良,尤其是腺癌患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验